Geron (GERN) Stock Forecast: StockMap's 2-Week Call
GERN stock forecast: StockMap's model makes no two-week call on Geron after the Nov 19 close: its evidence is split, 8 reasons for and 7 against. Too few two-week windows graded to judge yet.
Geron last closed at $0.91, -8.08% on the session.
Against the IVW growth benchmark the position is -5.75% over the forecast window.
Geron's market cap is $586.80M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 6 (too close to call).
Where GERN sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 8 bullish and 7 bearish.
Agreement across those insights is 53%.
1 daily call for GERN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Geron in the 26th percentile on return on equity, where 100 is best.
Geron is classified under Health Care / Biotechnology.
StockMap tracks Geron as the 163rd largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Geron ranks 43rd of 394 in the group, against a group median of -0.27.